Human trial11 anoca participants90 daysNon-randomised trial
Empagliflozin Improves Angina and Endothelial Dysfunction Indices in Angina and No Obstructive Coronary Arteries (ANOCA)
Arteriosclerosis, Thrombosis, and Vascular Biology
- Empagliflozin
- Apoptosis
- Inflammation
- Angina with no obstructive coronary artery disease
- Coronary artery vasospasm
- Humans
The paper
Danielle N. Tapp, Sukhleen Kaur, Olga Toleva, Odayme Quesada
Show 16 more authors
Paxson Tipler, Namrita D. Ashokprabhu, Pooja Acharya, Christian W. Schmidt, Leslie L. Korbee, Michelle S. Hamstra, Michael Tranter, Andreas Tzoumas, Ayushi Mohan, Shesh Nath Rai, Dirk Jan Duncker, John Francis Beltrame, Steven E.S. Miner, C. Noel Bairey Merz, Timothy D. Henry, Albert Phillip Owens,Christ Hospital
Arteriosclerosis, Thrombosis, and Vascular Biology · 1 Oct 2026
